Targeting ALK in neuroblastoma--preclinical and clinical advancements.
about
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapyPediatric solid tumor genomics and developmental pliancyNeuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid raftsAssessing the range of kinase autoinhibition mechanisms in the insulin receptor familyNovel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices.Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAIntegrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspectiveUltra-High Density SNParray in Neuroblastoma Molecular DiagnosticsThe ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.Therapeutic targets for neuroblastomas.Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastomaNeuroblastoma: developmental biology, cancer genomics and immunotherapy.Detection of tumor ALK status in neuroblastoma patients using peripheral blood.Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo.Drug discovery in paediatric oncology: roadblocks to progress.Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology groupTargeting developmental pathways in children with cancer: what price success?Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomasNeuroblastoma and MYCNPrimary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.ALK: a tyrosine kinase target for cancer therapy.Neuroblastoma treatment in the post-genomic era.Emerging drugs for neuroblastoma.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.New immunotherapeutic strategies for the treatment of neuroblastoma.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastomaEqual access to innovative therapies and precision cancer care.Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.Advances in emerging drugs for the treatment of neuroblastoma.Genetic susceptibility to neuroblastoma.Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma
P2860
Q26849503-F0704751-2A1D-43A7-B9ED-94032AAFE45DQ27023560-FCE7FF5C-4BB4-4C14-9B21-718795A87430Q27319837-E1FBC2A9-20F0-49E7-B3F9-CCC6FF84199FQ27673414-89E8D8C5-DC28-44DC-BEBC-F92D8C259B97Q27853323-D2ABE971-CC98-4BF1-B0A4-07157780D3F3Q30365308-78CE6C6E-F2D6-4442-9604-C607B8577A50Q30426051-CF7A9B73-AF02-4B3E-BE12-0A9988199E3FQ33737740-0FEAD48E-B266-444E-999D-E9CD51DC09EFQ33903573-E459380D-8236-41FF-AB0E-36307998E78BQ34032495-DBDAD645-86B1-4507-843A-B8CA0E9BDB96Q34221605-9EBABDD2-6AC1-4FEC-BB8B-C45D975B57EEQ34560877-37B6B7EC-5C3D-4666-A82E-BA5939EA7973Q35049970-C7E1440C-245F-41AE-879B-CA07392012A5Q35131527-0F191B1E-DF6A-4990-AF3B-6C009BD53FD6Q35283020-FC2A6AFC-6F16-45AB-B4FA-11A7BC36DAABQ35469393-D6891825-0362-4E51-AA98-3651CD0920E5Q35598158-32EC06F3-7FEA-48B5-9E26-236A202A255DQ36262295-7277E15C-6EF3-49FE-A0A5-53710EF5317AQ36378105-1B82A307-A27E-46FF-BB1D-ADA11A10A720Q36380013-BC7B5C6C-803C-4722-801E-63CDDEBF81B5Q36905620-5C6C9647-F5DD-4836-9F30-DE32748D8CB7Q37065337-F6FDCA6D-357F-4F4F-AAF9-4ED8371E1E9EQ37201479-36B0149F-AF15-43E8-9BCF-67A696C944C3Q37286919-A923016F-542A-4BF6-A7C1-92F8C96120E8Q37518624-6C7D7439-8077-4428-A743-A503CBB76F23Q37633731-EB0B8AB5-FA8B-4D1E-B64F-89AB21F14612Q38108399-6649574E-96CC-4ACE-9711-5EABB7268DEEQ38161274-D1194B19-9386-423B-847D-C53C8AD29953Q38389316-30BFAD1C-88A3-44ED-B9C4-0A33469EE94AQ38625880-89B09C53-B81B-44BB-BCE1-886DC2E86D9BQ38707447-C301F08E-D974-417B-B7BC-4331A398C383Q38741543-668F9E41-C13D-4A9B-A7A7-1D64C8A9DA61Q38784010-4D45A674-96CC-4453-A883-7D36BD033ADCQ38800617-BB768085-B12C-4302-BAA7-2F77BB6DEDCCQ39051444-00EBBF93-34FF-44EC-8FED-3EB1B06DB40EQ39158415-F0E31101-375E-4260-A5A0-1E3BC922C806Q39273903-85DB8E8B-5E0A-4D70-A8C4-76E8CD1AC3ADQ40991136-EEF9C586-F16D-4301-95AC-13B5F056F16EQ40999620-D46BBE64-C2AC-4395-8A4E-D2FBFE72CCB4Q41738897-9F267B6B-3F93-47A6-B813-A7AF7A78F89E
P2860
Targeting ALK in neuroblastoma--preclinical and clinical advancements.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting ALK in neuroblastoma--preclinical and clinical advancements.
@en
type
label
Targeting ALK in neuroblastoma--preclinical and clinical advancements.
@en
prefLabel
Targeting ALK in neuroblastoma--preclinical and clinical advancements.
@en
P2860
P1476
Targeting ALK in neuroblastoma--preclinical and clinical advancements.
@en
P2093
Erica L Carpenter
Yael P Mossé
P2860
P304
P356
10.1038/NRCLINONC.2012.72
P407
P577
2012-05-15T00:00:00Z